* Iterum Therapeutics PLC ITRM.OQ ITRM.O is expected
to show
no change in quarterly revenue when it reports results on May
13 for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Iterum Therapeutics PLC
is for
a loss of 72 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Iterum
Therapeutics PLC is $6.50, above its last closing price
of $1.55.
This summary was machine generated May 8 at 07:53 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)